Troubling Trial Data Weighed on Agenus Inc Stock Today

Troubling Trial Data Weighed on Agenus Inc Stock Today

What happened Shares of Agenus Inc (NASDAQ:AGEN), a biopharmaceutical company developing cancer therapies, had fallen about 14.5% as of 3:20 p.m. EST on Wednesday. Investors weren’t too thrilled about its cancer vaccine’s recent clinical trial failure. So what The Prophage G-200 vaccine involved using a patient’s own cancer cells to direct a prolonged immune response → Read More

Why Toll Brothers, Lantheus Holdings, and Norwegian Cruise Line Holdings Jumped Today

Why Toll Brothers, Lantheus Holdings, and Norwegian Cruise Line Holdings Jumped Today

The stock market once again proved its resiliency on Wednesday, bouncing back from extensive declines early in the session to recover most of its losses. The Dow Jones Industrials actually managed to post yet another record close with a modest gain, and although other major market benchmarks suffered declines, they weren’t significant. Moreover, some favorable → Read More

Trump supporters' chief complaint about Obamacare: It costs too much

Trump supporters' chief complaint about Obamacare: It costs too much

Some Trump supporters hoping they don’t lose Obamacare The deductibles are just too darn high. That’s the main issue President Trump’s supporters have with their Obamacare coverage, according to a new survey by the Kaiser Family Foundation. But they are also concerned that Republicans won’t solve the problem. Read More

3 New Must-Read Quotes From Walt Disney Co. Management

3 New Must-Read Quotes From Walt Disney Co. Management

After falling to lows around $90 toward the end of 2016, Walt Disney (NYSE:DIS) stock has rebounded to about $110. The recent rise may have some investors anxious for some good reasons to remain bullish on the stock at these levels. Fortunately, Disney management shared some reasons to be optimistic during its Feb. 7 earnings → Read More

American Airlines and United Airlines Start Selling Basic Economy Fares

American Airlines and United Airlines Start Selling Basic Economy Fares

A few years ago, Delta Air Lines (NYSE:DAL) introduced a new class of cheaper “basic economy” fares to help it compete with ultra-low cost carriers on certain routes. Last year, American Airlines (NASDAQ:AAL) and United Continental (NYSE:UAL) confirmed that they would introduce their own basic economy fares to stay competitive. Earlier this week, American and → Read More

Conservative provocateur targets CNN with secret recordings

Conservative provocateur targets CNN with secret recordings

James O’Keefe, pictured in 2015, says he plans to release secretly recorded material from inside CNN. Conservative provocateur James O’Keefe is setting his sights on CNN. O’Keefe said in a telephone interview with CNN on Wednesday that he has “a few hundred hours” of “secretly recorded material” from inside the network. “We’re calling it CNN → Read More

What Russia Beating Saudi Arabia at Its Own Game Means for Oil Stocks

What Russia Beating Saudi Arabia at Its Own Game Means for Oil Stocks

According to a recent report by the Joint Organisations Data Initiative, Russia edged out Saudi Arabia as the world’s largest oil producer in December. That was the first time the Russians had come out on top since March. Meanwhile, preliminary data compiled by Bloomberg for January showed an even wider gap between the two as → Read More

How High Can Corbus Pharmaceuticals Stock Go?

How High Can Corbus Pharmaceuticals Stock Go?

Corbus Pharmaceuticals (NASDAQ:CRBP) managed to become one of the top-performing biotech stocks on the market in 2016. Over the last 12 months, Corbus’ share price has soared 550%. It was a bumpy ride for shareholders, though. Corbus stock had some big drops along the way, most recently falling around 25% before clawing its way back. → Read More

Criteo Falls After Yet Another Great Quarter

Criteo Falls After Yet Another Great Quarter

Criteo SA (ADR) (NASDAQ:CRTO) announced stronger-than-expected fourth-quarter 2016 results Wednesday morning, highlighted by record new-client additions. But shares of the advertising retargeting specialist declined modestly as the market digested what appeared to be underwhelming guidance. Let’s have a closer look, then, at how Criteo capped the year, as well as what investors should expect going forward. Criteo → Read More

3 Ways GoPro Inc Is Losing to the Competition

3 Ways GoPro Inc Is Losing to the Competition

GoPro‘s (NASDAQ:GPRO) success in the action camera market hasn’t happened in a vacuum, and has certainly been noticed by competitors. And the company’s natural product line extensions are entering markets that competitors have already invested in heavily.  The crowded market shows: In early 2017, GoPro has been losing out to the competition in three areas → Read More

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.